Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed at a consistent dose rate.
They have invented a transparent adhesive patch that can consistently deliver a prolonged high dose of the painkiller ibuprofen directly through the skin. The University of Warwick researchers and Medherant have found a way to incorporate significant amounts of the drug (up to 30% weight) into the polymer matrix that sticks the patch to the patient’s skin with the drug then being delivered at a steady rate over up to 12 hours.
This opens the way for the development of a range of novel long-acting over-the-counter pain relief products which can be used to treat common painful conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally. Although there are a number of popular ibuprofen gels available these make it difficult to control dosage and are inconvenient to apply.
This novel patch incorporates polymer technology developed by the global adhesive company Bostik and exclusively licensed for transdermal use to Medherant.
The key features of Medherant’s new patch technology are:
- The patch remains highly tacky and thus adheres well to skin even when the drug load reaches levels as high as 30% of the weight/volume of the patch. The drug load made possible by this new technology can be 5 -10 times than that found in some currently used medical patches and gels.
- High drug load and a consistent drug release profile means the Medherant patches out-perform other patches and gels in their ability to deliver a consistent and significant dose of drug over a prolonged time from a small patch.
- It is a cosmetically pleasing transparent design with stronger adhesion than other commercial products – remaining stuck over its time of action but easy and comfortable to remove.
University of Warwick research chemist Professor David Haddleton said:
“Many commercial patches surprisingly don’t contain any pain relief agents at all, they simply soothe the body by a warming effect. Our technology now means that we can for the first time produce patches that contain effective doses of active ingredients such as ibuprofen for which no patches currently exist. Also, we can improve the drug loading and stickiness of patches containing other active ingredients to improve patient comfort and outcome.”
“There are only a limited number of existing polymers that have the right characteristics to be used for this type of transdermal patches – that will stick to the skin and not leave residues when being easily removed. Furthermore, there are also only a limited number of drugs that will dissolve into these existing polymers. Medherant’s technology now opens up the field of transdermal drug delivery to previously non-compatible drugs.”
“Our success in developing this breakthrough patch design isn’t limited to ibuprofen; we have also had great results testing the patch with methyl salicylate (used in liniments, gels and some leading commercial patches). We believe that many other over the counter and prescription drugs can exploit our technology and we are seeking opportunities to test a much wider range of drugs and treatments within our patch.”
Read more: Researchers create World’s first ibuprofen patch – delivering pain relief directly through skin
The Latest on: Pain relief
via Google News
The Latest on: Pain relief
- Lady Gaga health: ‘Chronic pain is no joke’ Singer discusses fibromyalgia conditionon January 20, 2021 at 7:01 am
LADY GAGA is one of the most successful music artists to take the industry by storm. She has a slew of awards to her name and has travelled around the world performing her latest tracks. And she does ...
- Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance Of New Drug Application For INP104 For The Acute Treatment Of Migraineon January 20, 2021 at 5:23 am
PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s 5O5(b)(2) New Drug ...
- 'It is illegal': man convicted after growing cannabis for pain reliefon January 19, 2021 at 7:00 pm
A man was found with more than two kilograms of cannabis in his Ballarat Central home last year that he was using to deal with pain, a court has heard.
- Pain Care Labs Receives 2020 Tibbetts Award for Innovationon January 19, 2021 at 4:05 pm
The industry leader in drug-free pain relief joins a select group of past awardees, including Qualcomm, 23andMe, Symantec, and Broadcom.
- Icy pain relief: Shelburne Falls woman turns cold shoulder to meds to treat connective tissue syndrome and fibromyalgiaon January 19, 2021 at 12:55 pm
As she waded into the water, barefoot and in a bathing suit, Carin Wales leaned over and used her hands to break through the thin sheet of ice that had formed atop the still water of the Deerfield ...
- Dr Relief Offers Revolutionary New Insoles That Help Fight Foot Pain and Plantar Fasciitison January 18, 2021 at 10:35 pm
Company offers a new, more affordable alternative to custom orthotics. Active men and women, as well as those whose line of work requires them to be on their feet for long ...
- Abbott to Launch App to Track and Report Pain Relief in Chronic Pain Patientson January 18, 2021 at 10:26 am
Abbott launches new app, NeuroSphere myPath that will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy ...
- How mice can ‘catch’ pain — and pain relief — from each otheron January 14, 2021 at 2:57 pm
Humans have been known to “catch feelings” from time to time, but mice are rubbing off on each other a feeling much worse: pain. On the other hand, they’re also benefitting from secondhand relief, ...
- Non-Opioid Pain Treatment Market 2021 Global Technology, Development, Trends and Forecasts to 2024 360 Market Updateson January 14, 2021 at 7:48 am
Opioid Pain TreatmentMarket ” Report 2021 - 2024 delivers the latest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and ...
- Covid-19 impact: Pain and Fever Relief Drugs Market to grow at a much faster rate beyond 2020| Financial Analysis and Forecaston January 13, 2021 at 10:58 pm
Market.Biz :Pain and Fever Relief Drugs Businesses must navigate the financial and operational challenges of coronavirus while rapidly addressing the needs of their people, customers, and suppliers.
via Bing News